Expert Analysis

CME

Key Studies in Myeloma: CCO Independent Conference Highlights of the 2020 Virtual ASH Annual Meeting

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: March 22, 2021

Expiration: March 21, 2022

Shaji K. Kumar
Shaji K. Kumar, MD
Sagar Lonial
Sagar Lonial, MD, FACP

Activity

Progress
1
Course Completed
Key Studies in MM at ASH 2020

In this module, Sagar Lonial, MD, and Shaji Kumar, MD, summarize key studies in multiple myeloma (MM) studies presented at the 2020 ASH Annual Meeting and Exposition. These studies included treatment options for patients with newly diagnosed MM or whose MM is relapsed/refractory (R/R) after several previous lines of therapy.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with multiple myeloma do you provide care for in a typical month?

Based on currently available evidence, which of the following treatment strategies would be the most likely to achieve a deep and durable remission for an active, fit 58-year-old patient who was newly diagnosed with active multiple myeloma?

When considering therapy with belantamab mafodotin for a patient with heavily pretreated relapsed/refractory multiple myeloma, which of the following is TRUE regarding the incidence of ocular toxicity/keratopathy?

You and a colleague are discussing encouraging findings presented at ASH 2020 from studies evaluating CAR T-cell therapy for relapsed/refractory multiple myeloma. Which of the following would you tell them is TRUE of the phase I CRB-402 trial, in which patients with relapsed/refractory multiple myeloma received the anti-BCMA CAR T-cell therapy bb21217, which is cultured with a PI3K inhibitor ex vivo with the goal of enriching for T-cells with memory-like phenotype?

Encouraging phase I data were presented at ASH 2020 for the novel agent pavurutamab in patients with heavily pretreated relapsed/refractory multiple myeloma. What type of immunotherapy is this agent?